EndoVascular Technologies suspends trials of vascular grafting system.
This article was originally published in The Gray Sheet
Executive Summary
ENDOVASCULAR TECHNOLOGIES SUSPENDS CLINICAL TRIALS of its EndoVascular Grafting Systems, discontinuing patient enrollment in both a Phase II study of its tube EndoGraft vascular graft implant and a Phase I study of its bifurcated EndoGraft. The company said it has "voluntarily temporarily suspended" the trials following discovery of breaks in the attachment system of the devices.